ruvector/examples/dragnes/docs/future-vision.md

DrAgnes 25-Year Future Vision (2026-2051)

Status: Research & Planning Date: 2026-03-21

Thesis

Skin cancer is the most common cancer globally, yet it is also the most visible and therefore the most detectable. In 25 years, late-stage melanoma detection should be as rare as late-stage cervical cancer in screened populations. DrAgnes is the platform that makes this possible by creating a continuously learning, globally distributed, privacy-preserving dermatology intelligence that evolves with medical knowledge.

Phase 1: Foundation (2026-2028)

Capabilities

• Mobile-first PWA with DermLite integration
• 7-class CNN classification (HAM10000 baseline)
• Offline-capable WASM inference (<200ms on mid-range phones)
• pi.ruv.io brain integration for collective learning
• HIPAA-compliant Google Cloud deployment
• ABCDE and 7-point checklist automation
• PubMed literature enrichment

Milestones

Date	Milestone
Q3 2026	MVP: DermLite + CNN + Brain integration, single-practice pilot
Q4 2026	HIPAA compliance audit, multi-practice beta
Q1 2027	10 practices, 10,000 classifications, model v2 training
Q2 2027	FDA pre-submission meeting (Class II 510(k) pathway)
Q4 2027	50 practices, publication of validation study results
Q2 2028	FDA 510(k) clearance (target)

Key Metrics

• 1,000 practices contributing to brain
• 1M+ classifications performed
• Melanoma sensitivity >95%, specificity >85%
• <200ms inference latency on WASM
• Model trained on 100K+ de-identified embeddings

Phase 2: Clinical Integration (2028-2032)

AR-Guided Biopsy and Surgery (2028-2030)

Augmented reality overlays on smartphone or AR glasses during dermatologic procedures:

AR Biopsy Guidance System
    │
    ├── Pre-Procedure Planning
    │       ├── 3D lesion mapping from multi-angle captures
    │       ├── Optimal biopsy site recommendation (highest Grad-CAM activation)
    │       ├── Margin calculation for excision (based on Breslow depth prediction)
    │       └── Anatomy overlay (nerves, vessels from atlas)
    │
    ├── Real-Time Guidance
    │       ├── AR overlay showing recommended biopsy boundaries
    │       ├── Depth estimation from dermoscopic features
    │       ├── Live tissue classification at incision margins
    │       └── Alert if approaching critical structures
    │
    └── Post-Procedure Documentation
            ├── Automatic photo documentation with annotations
            ├── Specimen labeling with QR-linked brain reference
            ├── Pathology correlation tracking
            └── Outcome learning (brain feedback loop)

Technology Requirements:

• AR framework: WebXR API for browser-based AR (no app installation)
• Depth sensing: LiDAR on iPhone Pro / ToF on Android flagships
• Registration: Fiducial-free surface registration via lesion landmarks
• Latency: <100ms for real-time overlay

Expanded Taxonomy (2028-2030)

Grow from 7 classes to 50+ lesion subtypes:

Melanocytic:

• Common nevus (junctional, compound, intradermal)
• Dysplastic/atypical nevus
• Blue nevus
• Spitz/Reed nevus
• Congenital melanocytic nevus
• Melanoma (superficial spreading, nodular, lentigo maligna, acral lentiginous, amelanotic)

Non-Melanocytic Malignant:

• Basal cell carcinoma (nodular, superficial, morpheaform, pigmented)
• Squamous cell carcinoma (in situ, invasive, keratoacanthoma)
• Merkel cell carcinoma
• Dermatofibrosarcoma protuberans
• Cutaneous lymphoma (mycosis fungoides)

Benign:

• Seborrheic keratosis
• Solar lentigo
• Dermatofibroma
• Hemangioma
• Angioma
• Pyogenic granuloma
• Sebaceous hyperplasia
• Clear cell acanthoma

Inflammatory (differential diagnosis):

• Psoriasis plaque
• Eczema
• Lichen planus
• Lupus (discoid)

Whole-Body Photography (2029-2031)

Total-body dermoscopic surveillance for high-risk patients:

Whole-Body Photography System
    │
    ├── Capture Protocol
    │       ├── Standardized 24-position body photography
    │       ├── DermLite close-up of each tracked lesion
    │       ├── 3D body surface reconstruction (photogrammetry)
    │       └── Automated lesion detection and counting
    │
    ├── Lesion Tracking
    │       ├── Assign persistent IDs to every detected lesion
    │       ├── Track changes between visits (growth, color, shape)
    │       ├── Flag new lesions since last visit
    │       ├── Flag changed lesions (ABCDE evolution scoring)
    │       └── Prioritize lesions for clinician review by risk score
    │
    └── Population Analytics
            ├── Lesion density maps by body region
            ├── UV exposure correlation (sun-exposed vs. protected sites)
            ├── Age-related lesion progression patterns
            └── Familial pattern detection (hereditary risk)

Teledermatology Integration (2029-2031)

Store-and-forward and live teledermatology with AI triage:

Teledermatology Workflow
    │
    ├── Primary Care Capture
    │       ├── PCP captures dermoscopic image with DermLite DL4
    │       ├── DrAgnes provides preliminary classification
    │       ├── Risk score determines urgency tier
    │       └── Automatic referral routing based on risk
    │
    ├── AI Triage
    │       ├── Tier 1 (Low Risk): "Monitor in 3 months" — no dermatologist review needed
    │       ├── Tier 2 (Moderate): Asynchronous dermatologist review within 48 hours
    │       ├── Tier 3 (High): Priority asynchronous review within 24 hours
    │       └── Tier 4 (Critical): Immediate synchronous video consult
    │
    └── Dermatologist Review
            ├── Brain-augmented case presentation (similar cases, literature)
            ├── One-click confirm/correct DrAgnes classification
            ├── Feedback loop improves AI for future triage
            └── Billing integration (CPT 96931-96936 for teledermatology)

EHR Integration (2030-2032)

Deep integration with major EHR systems:

• Epic FHIR R4 + CDS Hooks (real-time alerts in clinician workflow)
• Cerner/Oracle Health FHIR integration
• Modernizing Medicine EMA (dominant dermatology EHR) partnership
• SMART on FHIR app for embedded DrAgnes within EHR
• HL7 FHIR DiagnosticReport for structured reporting
• ICD-10 code suggestion based on classification

Phase 3: Advanced Imaging Fusion (2032-2040)

Confocal Microscopy Integration (2032-2035)

Reflectance Confocal Microscopy (RCM) provides cellular-level imaging in vivo:

Multi-Modal Imaging Fusion
    │
    ├── Dermoscopy (10x, surface/subsurface patterns)
    │       └── DrAgnes CNN: 576-dim embedding
    │
    ├── RCM (500x, cellular morphology)
    │       └── Dedicated RCM CNN: 576-dim embedding
    │
    ├── OCT (cross-sectional depth imaging)
    │       └── OCT CNN: 576-dim embedding
    │
    └── Fusion Model
            ├── Concatenated embedding: 1728-dim
            ├── Cross-attention between modalities
            ├── Modality-specific and shared features
            ├── Interpretability: which modality contributed to decision
            └── Classification: 100+ lesion subtypes

RCM Benefits:

• Cellular-level resolution without biopsy
• Can distinguish melanoma from benign nevus at the cellular level
• Reduces unnecessary biopsies by 50-70% in clinical studies
• Currently limited to specialized centers (10-15 in US)
• DrAgnes could democratize RCM interpretation via AI

Optical Coherence Tomography (2033-2036)

OCT provides cross-sectional depth imaging:

• Measure tumor thickness non-invasively (correlates with Breslow depth)
• Visualize dermal-epidermal junction
• Detect vascular patterns at depth
• Guide excision margins in real-time

Multispectral Imaging (2034-2037)

Beyond RGB, capture at specific wavelengths:

• 700-1000nm (near-infrared): Deeper tissue penetration
• 400-450nm (violet): Enhanced melanin contrast
• 540-580nm (green): Vascular pattern emphasis
• Spectral unmixing for quantitative chromophore analysis (melanin, hemoglobin, collagen)

Genomic Risk Integration (2035-2040)

Combine dermoscopic analysis with genetic risk profiles:

Genomic-Dermoscopic Fusion
    │
    ├── SNP Risk Panel (polygenic risk score)
    │       ├── MC1R variants (red hair/fair skin risk)
    │       ├── CDKN2A (familial melanoma)
    │       ├── BAP1 (tumor predisposition)
    │       ├── MITF (melanocyte development)
    │       └── 200+ GWAS-identified melanoma-associated SNPs
    │
    ├── Somatic Mutation Profiling (from biopsy when available)
    │       ├── BRAF V600E (50% of melanomas)
    │       ├── NRAS (20% of melanomas)
    │       ├── KIT (acral/mucosal melanomas)
    │       └── TERT promoter mutations
    │
    └── Integrated Risk Score
            ├── Prior: Genetic risk (lifetime melanoma probability)
            ├── Likelihood: Dermoscopic evidence (CNN + ABCDE + patterns)
            ├── Posterior: Combined risk assessment
            └── Recommendation: Personalized screening interval

Phase 4: Autonomous Intelligence (2040-2051)

Continuous Monitoring Wearables (2040-2045)

Skin-monitoring devices worn continuously:

Continuous Skin Monitoring
    │
    ├── Smart Patches
    │       ├── Flexible dermoscopic sensor arrays
    │       ├── Adhesive patches over high-risk lesions
    │       ├── Daily imaging with change detection
    │       ├── Battery-free (NFC-powered by phone)
    │       └── Alerts on significant change
    │
    ├── Smart Clothing
    │       ├── Embedded sensor arrays in undergarments
    │       ├── Whole-body coverage during daily wear
    │       ├── Low-resolution scanning (new lesion detection)
    │       ├── Triggered high-res capture on detection
    │       └── Washable, flexible electronics
    │
    └── Ambient Sensors
            ├── Smart mirrors with multispectral cameras
            ├── Daily whole-body scan during morning routine
            ├── Change detection vs. personal baseline
            ├── Privacy-preserving (on-device only)
            └── No behavior change required from patient

Smart Mirror System (2040-2045)

Smart Mirror Architecture
    │
    ├── Hardware
    │       ├── 4K camera behind one-way mirror
    │       ├── Multispectral LED illumination (visible + NIR)
    │       ├── Edge AI processor (TPU/NPU)
    │       ├── Encrypted local storage (90-day rolling)
    │       └── Wi-Fi for brain sync (de-identified only)
    │
    ├── Daily Scan (automated during bathroom use)
    │       ├── Face, neck, arms, upper body capture
    │       ├── Consistent positioning via skeleton tracking
    │       ├── 30-second scan, no user action needed
    │       └── Ambient notification if change detected
    │
    └── Intelligence
            ├── Personal baseline model (first 30 days of use)
            ├── Daily delta computation against baseline
            ├── New lesion detection (>2mm threshold)
            ├── Existing lesion change tracking
            └── Seasonal adjustment (tan variation)

Molecular-Level Imaging (2045-2050)

Next-generation in vivo imaging at molecular resolution:

• Raman spectroscopy: Molecular fingerprinting of skin lesions without biopsy
• Photoacoustic imaging: Combines laser excitation with ultrasound detection for molecular contrast
• Two-photon fluorescence microscopy: Intrinsic fluorescence of skin chromophores at cellular resolution
• Coherent anti-Stokes Raman scattering (CARS): Label-free chemical imaging

These modalities could enable non-invasive histopathology-equivalent diagnosis, eliminating the need for many biopsies.

Brain-Computer Interface for Clinical Gestalt (2045-2050)

The most speculative but potentially transformative phase:

Dermatology BCI System
    │
    ├── Non-Invasive Neural Interface
    │       ├── High-density EEG (256+ channels)
    │       ├── fNIRS (functional near-infrared spectroscopy)
    │       └── MEG (magnetoencephalography) at point-of-care
    │
    ├── Clinical Gestalt Capture
    │       ├── Record neural patterns when expert examines lesion
    │       ├── Identify "recognition signature" for malignancy
    │       ├── Capture subconscious pattern recognition
    │       └── Quantify clinical intuition
    │
    ├── Knowledge Transfer
    │       ├── Expert gestalt patterns stored in brain (de-identified)
    │       ├── Neural playback for trainee education
    │       ├── Augmented perception for non-specialists
    │       └── Clinical gestalt as a learnable embedding
    │
    └── Augmented Perception
            ├── Subconscious alert when viewing suspicious lesion
            ├── Enhanced pattern recognition via neural feedback
            ├── Attention guidance to dermoscopic features
            └── Reduced cognitive load during high-volume screening

Self-Evolving Diagnostic Models (2040-2051)

Models that discover new knowledge without human supervision:

Self-Evolving Architecture
    │
    ├── Unsupervised Cluster Discovery
    │       ├── Brain MinCut identifies emergent lesion clusters
    │       ├── New clusters flagged as potential novel subtypes
    │       ├── Cross-reference with PubMed for validation
    │       └── Propose new taxonomy entries to clinical community
    │
    ├── Anomaly-Driven Learning
    │       ├── Cases where model is uncertain → human review
    │       ├── Human review → new training data
    │       ├── New training data → model update
    │       └── Reduced uncertainty over time
    │
    ├── Cross-Domain Transfer
    │       ├── ruvector-domain-expansion crate
    │       ├── Transfer patterns from ophthalmology (fundoscopy → dermoscopy)
    │       ├── Transfer from pathology (histology → dermoscopy correlation)
    │       └── Transfer from radiology (imaging AI techniques)
    │
    └── Meta-Scientific Discovery
            ├── Identify correlations humans haven't noticed
            ├── Propose hypotheses for clinical validation
            ├── Automated literature review for supporting evidence
            └── Publish findings (AI-authored, human-reviewed)

Global Dermatology Knowledge Network (2035-2051)

The ultimate vision: every practice contributes, all benefit.

Global Network Architecture
    │
    ├── Federated Brain Constellation
    │       ├── Regional brains (Americas, EMEA, APAC, Africa)
    │       ├── Cross-regional knowledge sharing (privacy-preserving)
    │       ├── Regional model specialization (skin type distribution)
    │       └── Global consensus model (aggregate)
    │
    ├── Scale Projections
    │       ├── 2030: 10,000 practices, 100M classifications
    │       ├── 2035: 100,000 practices, 1B classifications
    │       ├── 2040: 500,000 practices, 10B classifications
    │       └── 2050: Universal coverage (every smartphone = dermatoscope)
    │
    ├── Impact Projections
    │       ├── 2030: 20% reduction in late-stage melanoma detection
    │       ├── 2035: 50% reduction in unnecessary biopsies
    │       ├── 2040: 70% reduction in late-stage melanoma detection
    │       └── 2050: Near-elimination of late-stage melanoma in connected populations
    │
    └── Equity Goals
            ├── Free tier for underserved communities
            ├── Offline-first for areas without reliable connectivity
            ├── Multilingual (50+ languages)
            ├── Fitzpatrick-fair across all skin types
            └── Open-source base model for research

Technology Roadmap

Year	Technology	DrAgnes Integration
2026	MobileNetV3 + WASM	Core CNN classifier
2027	WebXR API	AR biopsy guidance prototype
2028	FHIR R4 + CDS Hooks	EHR integration
2030	Miniaturized RCM	Multi-modal imaging fusion
2032	Flexible electronics	Smart patch monitoring
2035	Polygenic risk scores	Genomic-dermoscopic fusion
2037	Raman spectroscopy (handheld)	Molecular imaging
2040	Smart mirrors	Ambient continuous monitoring
2042	On-chip DNA sequencing	Point-of-care genomics
2045	Non-invasive BCI	Clinical gestalt capture
2050	Universal smartphone dermoscopy	Global coverage

Risks and Mitigations

Risk	Timeframe	Mitigation
AI regulation tightens	2026-2030	Early FDA engagement; design for compliance
DermLite discontinues or pivots	2026-2030	Device-agnostic design; multiple adapter support
Competing platform wins market	2026-2035	Unique brain learning advantage; open ecosystem
Bias in training data persists	2026-2040	Active fairness monitoring; diverse data acquisition
Clinician trust insufficient	2026-2035	Interpretability-first design; published validation studies
Privacy breach	Any	No raw images in cloud; witness chain audit trail
Technology plateau (CNN accuracy)	2030-2040	Multi-modal fusion; new imaging modalities
Wearable adoption slow	2040-2050	Smart mirror alternative; no behavior change required